The New Era of Bispecific Antibodies for Cancer Immunotherapy

Good news! Cancer is history (soon)!

From monoclonal antibodies to "bispecific antibodies (bsAbs) are emerging, with the ability to bind two different antigens or two different epitopes on the same antigen".

The New Era of Bispecific Antibodies for Cancer Immunotherapy | Sino Biological (open access)

Figure 1. Schematic diagram of bsAbs bridging tumor cells and T cells